In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Collagen

This article was originally published in The Gray Sheet

Executive Summary

Collagen: Plans to spin off its Collagen Technologies R&D business to Collagen shareholders by spring 1998, David Foster, senior VP and general manager of Collagen Technologies Group, stated at an Oct. 27 session of the Oppenheimer conference. Collagen announced plans to separate the operations from Collagen's Aesthetic Technologies businesses in January ("The Gray Sheet" Jan. 13, I&W-4)...

You may also be interested in...



UK Sunscreen Claims On ‘Negligible’ Difference In SPF Strengths Don't Add Up

Advertising Standards Authority says Green People Co. misled consumers with claims SPF 30 formulas filter out only 1% less UVB rays than SPF 50, trying to draw a negligible difference between the formulas. The claims appeared in a direct mailer and on the brand’s website in July 2019.

Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov

Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives. 
UsernamePublicRestriction

Register

MT009051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel